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Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type
2 (ACVR2) ligands through changes in protein synthesis/degradation. These changes
in cellular and protein metabolism may alter protein homeostasis. First, we elucidated
the acute (1–2 days) and 2-week effects of blocking ACVR2 ligands by soluble activin
receptor 2B (sACVR2B-Fc) on unfolded protein response (UPR), heat shock proteins
(HSPs) and redox balance in a healthy mouse skeletal muscle. Second, we examined
UPR, autophagy and redox balance with or without sACVR2B-Fc administration in
muscle and liver of C26 tumor-bearing mice. The indicators of UPR and HSPs were
not altered 1–2 days after a single sACVR2B-Fc administration in healthy muscles,
but protein carbonyls increased (p < 0.05). Two weeks of sACVR2B-Fc administration
increased muscle size, which was accompanied by increased UPR markers: GRP78
(p < 0.05), phosphorylated eIF2α (p < 0.01) and HSP47 (p < 0.01). Additionally, protein
carbonyls and reduced form of glutathione increased (GSH) (p < 0.05). On the other
hand, C26 cancer cachexia manifested decreased UPR markers (p-eIF2α, HSP47,
p-JNK; p < 0.05) and antioxidant GSH (p < 0.001) in muscle, whereas the ratio of
oxidized to reduced glutathione increased (GSSG/GSH; p < 0.001). Administration of
sACVR2B-Fc prevented the decline in GSH and increased some of the UPR indicators
in tumor-bearing mice. Additionally, autophagy markers LC3II/I (p < 0.05), Beclin-1
(p < 0.01), and P62 (p < 0.05) increased in the skeletal muscle of tumor-bearing
mice. Finally, indicators of UPR, PERK, p-eIF2α and GRP78, increased (p < 0.05),
whereas ATF4 was strongly decreased (p < 0.01) in the liver of tumor-bearing mice
while sACVR2B-Fc had no effect. Muscle GSH and many of the altered UPR indicators
correlated with tumor mass, fat mass and body mass loss. In conclusion, experimental
cancer cachexia is accompanied by distinct and tissue-specific changes in proteostasis.
Muscle hypertrophy induced by blocking ACVR2B ligands may be accompanied by the
induction of UPR and increased protein carbonyls but blocking ACVR2B ligands may
upregulate antioxidant protection.
Keywords: cancer cachexia, autophagy, myostatin, activin, unfolded protein response, glutathione, oxidative
stress/redox
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INTRODUCTION
Cachexia is characterized by loss of skeletal muscle mass with or
without reduction of fat mass and is common in diseases such as
cancer, chronic obstructive pulmonary disease and sepsis (Fearon
et al., 2011; Argiles et al., 2014; von Haehling and Anker, 2014).
Loss of skeletal muscle mass is an independent predictor of bad
prognosis in cancer (Martin et al., 2013; Choi et al., 2015). In
preclinical animal models, prevention of cancer-induced muscle
loss without an effect on tumor growth (Cai et al., 2004; Zhou
et al., 2010; Nissinen et al., 2018) suggests possible causality
between maintenance of muscle mass and improved survival in
cachexia, but the underlying mechanisms are unknown.
Cellular protein homeostasis (i.e., proteostasis) is
maintained through several integrated biological processes.
For instance, undesirably modified or misfolded proteins are
degraded by ubiquitin proteasome or autophagy lysosome
pathways (Schneider and Bertolotti, 2015; Sandri, 2016).
Additionally, disrupted cellular homeostasis induced by,
for example, robustly increased protein synthesis, aberrant
redox control or unbalanced endoplasmic reticulum (ER)
calcium homeostasis can lead to accumulation of misfolded
proteins into the lumen of ER, a process also known as ER
stress (Cao and Kaufman, 2014; Hetz et al., 2015). Cells
respond to ER stress in order to maintain homeostasis by
activating unfolded protein response (UPR). It is a process
which restores ER homeostasis by various mechanisms,
such as increasing protein folding machinery, degrading
misfolded proteins, suppressing protein synthesis and
inducing autophagy. If ER stress is not rescued by UPR,
metabolic impairments or apoptosis may occur (Hetz et al.,
2015).
In skeletal muscle, disrupted protein homeostasis has been
observed in wasting conditions and muscular dystrophies. This
has been manifested as increased ER stress and oxidative stress
in muscular dystrophies (Renjini et al., 2012; Screen et al.,
2014; Hulmi et al., 2016), and there is some evidence that
ER and oxidative stress are increased in some experimental
cancer cachexia models as well (Der-Torossian et al., 2013; Ham
et al., 2014; Bohnert et al., 2016). In skeletal muscle, cancer
cachexia has been reported to induce ER stress and UPR in 2
experimental animal models: Lewis lung carcinoma (LLC) and
cachectic Apcmin/+ mice (Bohnert et al., 2016). Interestingly,
UPR inhibition in cancer cachexia by chemical chaperone 4-PBA
accelerated muscle wasting in LLC and Apcmin/+ mice (Bohnert
et al., 2016). Very recently, skeletal muscle specific ablation
of PERK induced muscle wasting in healthy mice and further
increased muscle wasting in LLC tumor bearing mice (Gallot
et al., 2018). In addition to skeletal muscle, increased ER stress in
the liver has been observed in cachectic Apcmin/+ mice (Narsale
et al., 2015). Upregulated and/or impaired autophagy has also
been reported in cancer cachexia (Penna et al., 2013; Aversa
et al., 2016). It is unknown if UPR is ubiquitously induced in
other wasting and cachexia models such as in C26 tumor-bearing
mice.
Blocking activin receptor ligands using the soluble ligand
binding domain of a type 2B activin receptor fused to the Fc
domain (sACVR2B-Fc) rapidly increases muscle size in mice (Lee
et al., 2005; Zhou et al., 2010; Pistilli et al., 2011; Hoogaars et al.,
2012; Hulmi et al., 2013a) and in humans (Attie et al., 2013). This
occurs through increased protein synthesis (Hulmi et al., 2013a;
Nissinen et al., 2016) but possibly in some situations through
decreased protein degradation (Zhou et al., 2010). Increased
muscle mass may not, however, always translate into better
muscle function (Amthor et al., 2007; Relizani et al., 2014),
perhaps in part due to qualitative changes in muscle (Amthor
et al., 2007; Relizani et al., 2014; Hulmi et al., 2016; Marabita et al.,
2016). However, the effect of rapid muscle hypertrophy induced
by an activin receptor ligand blockade on protein homeostasis is
currently unknown. We previously reported improved survival in
C26 tumor-bearing mice with sACVR2B-Fc treatment (Nissinen
et al., 2018). Cachectic mice had decreased protein synthesis
in skeletal muscle and increased protein synthesis in the liver,
the latter of which was alleviated by sACVR2B-Fc treatment
(Nissinen et al., 2018). Thus, we further investigated the effects
of cancer cachexia and sACVR2B-Fc treatment on protein
homeostasis in muscle and the liver.
The purpose of this study was to elucidate the effects of muscle
wasting induced by cancer cachexia, and muscle hypertrophy
induced by sACVR2B-Fc treatment on biological processes
contributing to the protein and redox homeostasis in skeletal
muscle. Furthermore, because skeletal muscle and the liver are
known to crosstalk (Whitham et al., 2018), we explored the effects
of cancer and sACVR2B-Fc treatment on protein homeostasis in
the liver as well. We hypothesized that both rapid atrophy and




The treatment of the animals was in strict accordance with
the European convention for the protection of vertebrate
animals used for experimental and other scientific purposes.
The protocols were approved by the National Animal
Experiment Board (Permit No.: ESLH-2009-08528/Ym-23
and ESAVI/10137/04.10.07/2014).
Animals and Cells
Single and 2-Week Administration of sACVR2B-Fc on
Healthy Mice
Male, 6–7-week-old C57Bl/10SnJ mice were used as previously
described (Hulmi et al., 2013a). The mice were purchased from
the Jackson Laboratory (Bar Harbor, ME, United States).
The Cancer Cachexia Experiments
In the cancer cachexia experiments, 5–6-week-old male BALB/c
(BALB/cAnCrl) mice (Charles River Laboratories) were used. All
the mice were housed in standard conditions (temperature 22◦C,
light from 8:00 AM to 8:00 PM) and had free access to tap water
and food pellets (R36, 4% fat, 55.7% carbohydrate, 18.5% protein,
3 kcal/g, Labfor, Stockholm, Sweden).
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Tumor Cell Culture
Complete Dulbecco’s Modified Eagle’s Medium (DMEM,
high glucose, GlutaMAXTM Supplement pyruvate, GibcoTM,
Life Technologies) supplemented with penicillin (100 U/ml),
streptomycin (100 µg/ml) and 10% FBS was used for the
maintenance of the colon 26 carcinoma cells as previously
described (Nissinen et al., 2018).
Experimental Design
This study consisted of three separate experiments (Figure 1),
which are described in detail below.
Acute sACVR2B-Fc Experiment in Healthy Mice
To study the acute effects of sACVR2B-Fc administration in
healthy skeletal muscle, mice were divided into three groups that
were euthanized 1 or 2 days after a single injection of PBS (i.p.)
or sACVR2B-Fc (10 mg/kg, i.p.) as previously described (Hulmi
et al., 2013a; Figure 1A).
Two-Week sACVR2B-Fc Experiment in Healthy Mice
To study the short-term effects of sACVR2B-Fc administration
in healthy skeletal muscle, mice were randomly divided into
mice administered (i.p., 1–2 times per week) with (1) PBS or
(2) sACVR2B-Fc as previously described (Hulmi et al., 2013a;
Figure 1B).
Cancer Cachexia Experiment
Mice were randomized into one of the four weight-matched
groups: (1) vehicle-treated (PBS) healthy control mice (CTRL),
(2) C26 tumor-bearing mice administered with a vehicle (PBS)
(C26 + PBS), (3) C26 tumor-bearing mice administered with
sACVR2B-Fc before the C26 tumor formation and replaced by
a vehicle (PBS) after the tumor formation (C26 + sACVR/b),
and (4) C26 tumor-bearing mice continuously administered with
sACVR2B-Fc throughout the experiment (C26 + sACVR/c).
Cancer groups were inoculated subcutaneously (s.c.) with C26
colon carcinoma cells (5 × 105 cells in ∼ 120 µl PBS) into
their interscapular region. The vehicle (PBS) and sACVR2B-
Fc (5 mg/kg in ∼ 100 µl PBS) were administered (i.p.) every
fourth day (Figure 1C). The weight loss from day 10 to
11 after C26 inoculation strongly predicted survival (Nissinen
et al., 2018) and thus the end-point was chosen to be 11 days
after the C26 inoculation to represent the onset of cachexia.
When the symptoms of cancer started to occur, mice were
strictly and carefully monitored according to the end-point
guidelines of animal experiments approved by the National
Animal Experiment Board. However, none of the mice fulfilled
the end-point criteria before the actual end-point.
sACVR2B-Fc Production
The production of the recombinant sACVR2B-Fc, which is
similar but not totally identical with the original version
generated by Lee et al. (2005), has been described in detail before
(Hulmi et al., 2013a). Briefly, we fused a human IgG1 Fc domain
with the ectodomain of human ACVR2B and the protein was
expressed in Chinese hamster ovary cells grown in suspension
culture.
Tissue Collection and Processing
Tissue Collection
In the acute and 2-week experiments the mice were euthanized
by cervical dislocation and gastrocnemius muscles were weighed
and subsequently flash frozen in liquid nitrogen and stored at
−80◦C for further analysis. In the cancer experiment mice were
euthanized by cervical dislocation after heart puncture under
anesthesia [ketamine (Ketaminol R©):∼110–120 mg/kg+ xylazine
(Rompun R©): 15–16 mg/kg]. Gastrocnemius, tibialis anterior (TA)
and liver were weighed and flash frozen in liquid nitrogen and
were stored at−80◦C for further analysis.
RNA Extraction and cDNA Synthesis
In the cancer cachexia experiment, total RNA was extracted
from gastrocnemius muscles with QIAzol and were purified with
RNeasy Universal Plus kit (Qiagen). The quality of RNA was
confirmed by spectrophotometry (NanoDrop; Thermo Fisher
Scientific) and agarose gel electrophoresis. iScriptTM Advanced
cDNA Synthesis Kit (Bio-Rad Laboratories) was used to reverse
transcribe the RNA to cDNA. Both steps were conducted
according to the manufacturer’s guidelines.
Protein Extraction and Content Measurement
Muscle and liver samples were homogenized in ice-cold buffer
with protease and phosphatase inhibitors as previously described
(Hulmi et al., 2013a; Nissinen et al., 2018). The total protein
content was measured using the bicinchoninic acid protein assay
(Pierce Biotechnology, Rockford, IL, United States) with an




mRNA expression levels were analyzed with RT-qPCR following
standard procedures using iQ SYBR Supermix (Bio-Rad
Laboratories) and CFX96 real-time PCR Detection system. The
mRNA levels of Chop/Ddit3 (assay ID qMmuCID0020314),
Lc3b (assay ID qMmuCED0048150), and P62 (assay ID
qMmuCID0024517) were measured with pre-designed and
pre-validated primers (Bio-Rad PrimePCRTM SYBR Green
assays). The protocol recommended by the manufacturer
was used. The spliced variant mRNA level of X-box
binding protein 1 (Xbp1s) was analyzed using SYBR green
primers: forward: TGCTGAGTCCGCAGCAGGTG and
reverse: CTGATGAGGTCCCCACTGACAGA (Invitrogen,
United States). The protocol for the Xbp1s was initiated at
95◦C which was followed by 39 cycles of denaturation at
95◦C for 10 s, annealing at 61◦C for 30 s and extension
at 68◦C for 30 s. mRNA expression levels were calculated
from the exponential amplification phase using the
efficiency corrected 11CT method. 36b4 (Forward primer:
5′-GGCCCTGCACTCTCGCTTTC-3′, Reverse primer: 5′-
TGCCAGGACGCGCTTGT-3′) was used as a house-keeping
reference gene because it was unaffected by the cancer and
the sACVR2B-Fc treatments as previously reported (p > 0.16)
(Nissinen et al., 2018).
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FIGURE 1 | Overall study design. (A) Healthy mice were administered (i.p.) with a single dose of vehicle (PBS) or soluble activin receptor type 2B (sACVR) to block
ACVR2B ligands. Muscles were collected either 1 or 2 days after the single sACVR or vehicle administration (n = 6–7 per group). (B) Healthy mice were administered
(i.p.) with vehicle (PBS) or sACVR for 2 weeks (1–2 times per week) and muscles were collected (n = 6 in PBS and n = 11 in sACVR 2wk). (C) C26 cancer
experiment: (1) CTRL (+PBS, n = 9), (2) C26 + PBS (n = 7), (3) C26 + sACVR/b (n = 7), and (4) C26 + sACVR/c (n = 8). Cancer groups were inoculated
subcutaneously (s.c.) with C26 cells on day 11. The vehicle (PBS) and sACVR2B-Fc were administered (i.p.) every fourth day. Muscles and livers were collected
11 days after the C26 cell inoculation.
Western Blot
Western blot analyses were conducted in two laboratories and
therefore slightly different protocols are provided below:
LC3B, P62, Bcl-2, Beclin-1, p-ULK1ser757, ULK1, PERK,
p-eIF2αser51, total eIF2α, IRE1α, p-JNK54, JNK54, PDI, ATF4,
Cleaved Caspase 3 and 12 as well as HSP25, GRP78, and HSP47
were analyzed only from the cancer experiment by a protocol
previously described in more detail (Hulmi et al., 2013a; Hentila
et al., 2018). In short, muscle and liver homogenates mixed with
Laemmli sample buffer + β-mercaptoethanol were heated at
95◦C to denature proteins. Proteins were separated with SDS–
PAGE and transferred to a PVDF membrane, blocked (5% fat-free
milk in TBS-T) and incubated overnight at 4◦C with primary
antibodies. The membrane was then washed and incubated with
secondary antibodies (Jackson ImmunoResearch Laboratories,
West Grove, PA, United States) for 1 h followed by washing.
Proteins were visualized by enhanced chemiluminescence
(SuperSignal West Femto maximum sensitivity substrate, Pierce
Biotechnology, Rockford, IL, United States) using a ChemiDoc
XRS device and quantified with Quantity One software (version
4.6.3. Bio-Rad Laboratories, Hercules, CA, United States).
The uniformity of the protein loading was confirmed by
staining the membrane with Ponceau S and by re-probing
the membrane with an antibody against GAPDH (Abcam,
Cambridge, United Kingdom). The results were normalized to
the mean of Ponceau S (strong band at ∼42 kDa) and GAPDH
value.
HSP60, HSP70, HSP90 TRX, and TxNIP as well as GRP78,
HSP25, and HSP47 were analyzed from the acute experiments
by a protocol as described previously (Atalay et al., 2004;
Lappalainen et al., 2009). Briefly, protein extracts (20 µg protein
per well) with molecular weight markers were electrophoresed
on SDS/PAGE and transferred to a nitrocellulose membrane
(Millipore, Bedford, MA, United States). The uniformity of
the protein loading was confirmed by staining the membrane
with Ponceau S and by re-probing the membrane with an
antibody against Actin (Sigma, A-2066). Membranes were
blocked with 5% fat-free milk solution at 37◦C for 1 h and
treated with monoclonal or polyclonal antibodies overnight at
4◦C (StressGen, VIC, Canada; IMCO, Stockholm, Sweden; MBL
International, Woburn, MA, United States; Sigma, St. Louis, MO,
United States). Immunoblots were visualized by Odyssey (LI-
COR Biosciences Inc., Lincoln, NB, United States) and quantified
by Odyssey Software.
Antibodies
Antibodies for IRE1α (#3294), PDI (#3501), PERK (#3192),
eIF2α (#5324) and its phosphorylated form at ser51 (#3398,
p-eIF2αser51) GRP78 (used in the cancer experiment, #3177), P62
(#5114), Bcl-2 (#3498), p-ULK1ser757 (#14202), ULK1 (#8054),
p-JNKThr183/Tyr185 (#4668), JNK (#9252), ATF4 (#11815), Beclin-
1 (#3495), caspase 12 (#2202), and cleaved caspase 3 (#9661)
were purchased from Cell Signaling Technology. GAPDH
(ab9485) antibody was purchased from Abcam (Cambridge,
United Kingdom). LC3I and LC3II were measured by antibody
(L7543) that was purchased from Sigma-Aldrich (St. Louis, MO,
United States). Monoclonal primary antibodies were used for the
detection of heat shock protein 70 (HSP70, StressGen, SPA-810),
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heat shock protein 60 (HSP60, StressGen, SPA-806), heat shock
protein 90 (HSP90, StressGen, SPA-835), heat shock protein 47
(HSP47, StressGen, SPA-470) and thioredoxin interacting protein
(TXNIP and MBL). Polyclonal primary antibodies were used to
detect thioredoxin (TRX, IMCO, and ATRX-06), actin (Sigma, A-
2066), heat shock protein 25 (HSP25, StressGen, and SPA-801),
glucose-regulated protein 78 (GRP78, StressGen, SPA-826, used
in the acute experiments). Horseradish peroxidase conjugated
IgG secondary antibodies were used (Jackson ImmunoResearch
Laboratories, PA, United States and StressGen and Zymed,
San Francisco, CA, United States).
Analysis of Protein Carbonyls
In the acute and 2 weeks experiments protein carbonyls were
analyzed by western blot technique after derivatization with 2,4-
dinitrophenyl hydrazine immediately before the electrophoresis,
as previously described (Hulmi et al., 2016). In the C26
cancer experiment, the principle of the measurement was the
same as with acute and 2 weeks experiment. However, the
measurement was carried out with a commercial OxyBlot Protein
Oxidation Detection kit (Merck Millipore, S1750) according
to manufacturer’s instructions as previously described (Hentila
et al., 2018).
Glutathione Assays
After gastrocnemius muscle homogenization, total glutathione
(TGSH) was measured spectrophotometrically by an oxidized
glutathione (GSSG) reductase recycling method as described
earlier (Lappalainen et al., 2009; Hulmi et al., 2016). The rate
of change in absorbance at 412 nm was monitored with a
double-beam spectrophotometer at room temperature and tissue
concentrations were estimated by linear regressions from the
standard curve.
Statistical Methods
The main effect was analyzed by one-way analysis of variance
(ANOVA) or the Kruskal-Wallis test, followed by Holm-
Bonferroni corrected LSD or Mann-Whitney U post hoc tests
depending on the distribution of the data (Shapiro-Wilk).
The effect of 2-week sACVR2B-Fc (sACV 2wk vs. PBS 2wk)
administration was examined with Student’s t test or Mann
Whitney U if data were not normally distributed. The C26 cancer
effect (CTRL vs. C26 + PBS and CTRL vs. C26 groups pooled)
was analyzed with Student’s t test or the Mann-Whitney U-test
when data were not normally distributed. Correlations were
analyzed using Pearson’s product-moment coefficient.
PASW statistics version 24.0 was used for statistical analyses
(SPSS, Inc., Chicago, IL, United States). The level of significance
was set at P ≤ 0.05. Data are expressed as means± SE.
RESULTS
Background Results
This is a follow-up study on our two previous studies. In brief,
in Nissinen et al. (2018) we showed that C26 tumor implantation
resulted in muscle and fat wasting and increased hepatic protein
synthesis as well as acute phase response, a cytokine-induced
early defense mechanism (Cray et al., 2009). Treating mice with
sACVR2B-Fc increased muscle mass and protein synthesis in
healthy mice (Hulmi et al., 2013a) and prevented muscle loss and
prolonged survival in tumor-bearing mice without affecting the
tumor size when sACVR2B-Fc was administered continuously
before and after the C26 cell inoculation (Nissinen et al., 2018).
Two-Week sACVR2B-Fc Administration
Induces Unfolded Protein Response
The protein content of UPR indicators and ER-resident
chaperones were unchanged 1 and 2 days after the single
sACVR2B-Fc administration (Figures 2A–G) when muscle
protein synthesis was greatly induced (Hulmi et al., 2013b).
Later, after 2 weeks of sACVR2B-Fc administration, the
phosphorylation of eIF2αSer51 (p < 0.05) was increased without
changes in total eIF2α (Figures 2A,B). In addition, ER resident
chaperones GRP78 (p < 0.05) and HSP47 (p < 0.01) were
increased (Figures 2C,D), suggesting partial induction of UPR by
2-week sACVR2B-Fc administration, while other UPR indicators
were unchanged (PERK, PDI, and IRE1α) (Figures 2E–G).
Protein Carbonylation and the Reduced
Form of Glutathione Are Increased by
sACVR2B-Fc Administration
As a marker of oxidative damage, protein carbonyls were
increased 1 and 2 days after the sACVR2B-Fc administration in
skeletal muscle (Day 1: p < 0.05, Day 2: p = 0.06, Figure 3A) and
remained increased after 2 weeks of sACVR2B-Fc administration
(p < 0.05) (Figure 3A). Possibly as a delayed response to
increased oxidative stress, there was an increase in reduced
glutathione (p < 0.05, Figure 3B) and a trend for increased TRX
protein content (p = 0.10, Figure 3E) after 2 weeks of sACVR2B-
Fc administration without changes in the protein content of
TxNIP (Figure 3F). Oxidized glutathione (GSSG) concentration
(Figure 3C) and the ratio of oxidized and reduced glutathione
(GSSG/GSH) (Figure 3D) were unchanged by the sACVR2B-Fc
administration in all the time-points. Of the heat shock response
indicators, 2-week sACVR2B-Fc administration increased only
the protein content of small heat shock protein 25 (HSP25) at
2 weeks (p < 0.001, Figure 4A) without changes in larger HSPs
60, 70, and 90 at any time-point (Figures 4B–D).
Decreased Glutathione Levels in C26
Tumor-Bearing Mice Are Restored by
Continued sACVR2B-Fc Administration
Next, we investigated the effects of the C26 tumor that
induced cachexia and sACVR2B-Fc administration that alleviated
cachexia. As a marker of skeletal muscle redox balance, the
reduced form of glutathione was decreased in PBS-treated
tumor-bearing mice compared with healthy controls (p < 0.001,
Figure 5A). This was accompanied by increased ratio of oxidized
glutathione and reduced glutathione (GSSG/GSH), suggesting
increased oxidative stress (p < 0.001, Figure 5B). Interestingly,
sACVR/c administration prevented the decrease in reduced
glutathione levels (p < 0.05), thus decreasing the GSSG/GSH
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FIGURE 2 | Unfolded protein response (UPR) markers in healthy skeletal muscle in mice that were administered with soluble activin receptor type 2B (sACVR) or
vehicle (PBS). Muscles were collected 1 or 2 days after a single sACVR administration or after 2 weeks of administration. (A) p-eIF2αser51, (B) total eIF2α protein,
(C) GRP78 protein, (D) HSP47 protein, (E) PDI protein, (F) PERK protein, (G) IRE1α protein; n = 6–7 in all groups except n = 9–11 in sACVR 2 Wk group. The
symbol ∗ depicts statistical significance p < 0.05 whereas the symbol ∗∗ depicts statistical significance p < 0.01. Data is expressed as means ± SE. Representative
blots were cropped from the original blot images (Supplementary Figures 6–8). Representative blots with same IDs and analyzed in the same run are aligned on
top of each other and share the same representative control blot (GAPDH or actin).
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FIGURE 3 | Redox-balance markers in healthy skeletal muscle in mice that were administered with soluble activin receptor type 2B (sACVR) or vehicle (PBS).
Muscles were collected 1 or 2 days after a single sACVR administration or after 2 weeks of administration. (A) Protein carbonyls, (B) reduced glutathione (GSH), (C)
oxidized glutathione (GSSG), (D) ratio of oxidized glutathione to reduced glutathione (GSSG/GSH), (E) TRX protein, (F) TxNIP protein; n = 5–6 in all groups except
n = 8–11 in sACVR 2 Wk group. The symbol ∗ depicts statistical significance p < 0.05. Data is expressed as means ± SE. Representative blots were cropped from
the original blot images (Supplementary Figure 7). Representative blots of TRX and TxNIP share the same IDs and were analyzed in the same run and are thus
aligned on top of each other and share the same representative control blot (actin). Protein carbonyls were normalized to total protein loading.
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FIGURE 4 | Heat shock protein (HSP) response markers in healthy skeletal muscle in mice that were administered with soluble activin receptor type 2B (sACVR) or
vehicle (PBS). Muscles were collected 1 or 2 days after a single sACVR administration or after 2 weeks of administration. (A) HSP25, (B) HSP60, (C) HSP70, and
(D) HSP90; n = 6–7 in all groups except n = 10–11 in sACVR 2 Wk group. The symbol ∗∗∗ depicts statistical significance p < 0.001. Data is expressed as
means ± SE. Representative blots were cropped from the original blot images (Supplementary Figure 8). Representative blots with same IDs and analyzed in the
same run are aligned on top of each other and share the same representative control blot (actin).
ratio (pooled sACVR effect, p < 0.05) (Figure 5B). Oxidized
glutathione concentration (GSSG) (Figure 5C) and a marker of
oxidative damage/stress, protein carbonyl content were unaltered
by cancer and sACVR2B-Fc treatment (Figure 5D).
Cancer Cachexia Is Associated With
Decreased HSP47, p-eIF2α, and p-JNK54
of the UPR Indicators in Muscle
Of the UPR markers, C26 cancer decreased the phosphorylation
of eIF2α at Ser51 and the phosphorylation of JNK54 at
Thr183/Tyr185, as well as decreased the levels of HSP47 protein
in skeletal muscle (p < 0.05, Figure 6A). In addition, the
mRNA level of the pro-apoptotic indicator Chop tended to be
decreased when tumor-bearing groups were pooled (p = 0.06,
Figure 6B). Other UPR indicators remained unaltered by C26
cancer (Figures 6A,C). The continued sACVR2B treatment
(sACVR/c) increased GRP78 protein (p < 0.05) compared to
PBS-administered mice and tended to increase p-eIF2αSer51
(p = 0.18), HSP47 (p = 0.11), and p-JNK54 (p = 0.14) to
healthy control levels (Figure 6A). A mitochondrial UPR marker
HSP10 and HSP25 were unaltered by C26 cancer (Figures 6D,E).
However, when sACVR2B treated groups were pooled, HSP25
protein was increased compared to PBS-treated C26 tumor-
bearing mice (p < 0.05, Figure 6E).
Selective Hepatic UPR Is Induced in
Tumor-Bearing Mice
In the liver, the UPR indicators PERK (p < 0.05), p-eIF2αSer51
(p < 0.01) (no change in total eIF2α) and GRP78 (p < 0.001)
were increased by C26 cancer (Figures 7A–D). However, ATF4
protein content was greatly decreased (p < 0.01, Figure 7E)
and there was a trend for decrease in IRE1α (p = 0.053,
Figure 7F). Phosphorylation of JNK was unaltered by cancer
(Figure 7G) but total JNK was increased in tumor-bearing mice
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FIGURE 5 | Redox balance markers in skeletal muscle of C26 tumor-bearing mice. (A) Reduced glutathione (GSH), (B) ratio of oxidized to reduced glutathione
(GSSG/GSH), (C) oxidized glutathione (GSSG), and (D) protein carbonyls. CTRL, vehicle-treated (PBS) healthy control mice, n = 7–9. C26 + PBS = C26
tumor-bearing mice administered with a vehicle (PBS), n = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with sACVR before the tumor formation and
replaced by a vehicle (PBS) after the tumor formation, n = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously administered with sACVR throughout the
experiment, n = 8. The symbol ∗ depicts statistical significance p < 0.05 whereas the symbol ∗∗∗ depicts statistical significance p < 0.001. For the pooled effect
sACVR administered groups were pooled. Data is expressed as means ± SE. Protein carbonyls were normalized to Ponceau S staining (strongest band at
∼42 kDa). Representative protein carbonyl blot was cropped from the original blot image (Supplementary Figure 10).
when groups were pooled (p < 0.05, Figure 7H). sACVR2B-Fc
administration had no significant effect on any of the variables.
Pro caspase 12 was decreased (p < 0.05) by C26 cancer but
its cleaved form was unchanged (Supplementary Figure 1).
In addition, cleaved caspase 3 (Supplementary Figure 1) was
unchanged, suggesting that apoptosis was not activated at this
time point.
Autophagy-Lysosome Pathway Is
Induced in Skeletal Muscle and Liver of
Tumor-Bearing Mice
In skeletal muscle, lipidated LC3 (LC3II) (p = 0.051) and the
ratio of LC3II to LC3I (p < 0.05) which can be used as a
marker of autophagosome content, were both increased by the
C26 cancer (Figure 8A). In addition, Beclin-1, involved in
autophagy induction was increased by C26 cancer (p < 0.01,
Figure 8A). Moreover, the protein content of P62, which acts as
an adaptor protein sequestering cellular compartments that are to
be degraded by autophagy–lysosome pathway, was also increased
by C26 cancer (p < 0.01, Figure 8A). Lc3b mRNA (p < 0.05,
Figure 8C) was increased by cancer whereas the protein content
of LC3I, p-ULK1Ser757 as well as total ULK1 and Bcl-2 and p62
mRNA were unaltered (Figures 8A,B).
LC3II (p < 0.05), LC3II/I (p < 0.01), and Beclin-1 (p < 0.05)
increased in the liver by the C26 cancer without changes
in p-ULK1Ser757 and P62 protein (Figure 8D). Contrary to
skeletal muscle, LC3I (p < 0.05) increased in the liver by
C26 cancer. The discontinued administration of sACVR2B-Fc
further increased LC3II/I in skeletal muscle compared to other
tumor-bearing groups (p < 0.01, Figure 8A). Otherwise there
were no systematic effects of sACVR2B-Fc administration on
the autophagy indicators in skeletal muscle or in the liver
(Figures 8A–D).
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FIGURE 6 | Unfolded protein response (UPR) and heat shock protein (HSP) response markers in skeletal muscle of C26 tumor-bearing mice. (A) Protein content of
UPR markers (PERK, p-eIF2αser51, eIF2α, GRP78, HSP47, IRE1α, p-JNK54, JNK54, and PDI), (B) mRNA level of Chop, and (C) of spliced Xbp1 (Xbp1s). (D) Protein
content of HSP10 and (E) HSP25. CTRL, vehicle-treated (PBS) healthy control mice, n = 7. C26 + PBS = C26 tumor-bearing mice administered with a vehicle (PBS),
n = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with sACVR before the tumor formation and replaced by a vehicle (PBS) after the tumor formation,
n = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously administered with sACVR throughout the experiment, n = 8. The symbol ∗ depicts statistical
significance p < 0.05. For the C26 effect all the tumor-bearing groups were pooled. For the sACVR pooled effect both of the sACVR groups were pooled. Data is
expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figures 9, 10). Representative blots with same IDs
and analyzed in the same run are aligned on top of each other and share the same representative control blot (GAPDH).
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FIGURE 7 | Unfolded protein response (UPR) markers in the liver of C26 tumor-bearing mice. (A) PERK protein, (B) p-eIF2αser51, (C) eIF2α, (D) GRP78 protein,
(E) ATF4 protein, (F) IRE1α protein, (G) mean of p-JNK46 and p-JNK54, and (H) mean of total JNK46 and JNK54 protein. CTRL, vehicle-treated (PBS) healthy
control mice, n = 9. C26 + PBS = C26 tumor-bearing mice administered with a vehicle (PBS), n = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with
sACVR before the tumor formation and replaced by a vehicle (PBS) after the tumor formation, n = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously
administered with sACVR throughout the experiment, n = 8. The symbol ∗ depicts statistical significance p < 0.05, the symbol ∗∗ depicts statistical significance
p < 0.01 and the symbol ∗∗∗ depicts statistical significance p < 0.001. For the C26 effect, tumor-bearing groups were pooled. Data is expressed as means ± SE.
Representative blots were cropped from the original blot images (Supplementary Figures 11, 12). Representative blots with same IDs and analyzed in the same
run are aligned on top of each other and share the same representative control blot (GAPDH).
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FIGURE 8 | Autophagy markers in skeletal muscle and the liver of C26 tumor-bearing mice. (A) Protein content of autophagy markers in skeletal muscle (LC3II,
LC3I, LC3II/LC3I, P62, Beclin-1, p-ULK1ser757, total ULK1, and Bcl-2). The mRNA level of (B) P62 and (C) Lc3b in skeletal muscle. (D) Protein content of autophagy
markers in the liver (LC3II, LC3I, LC3II/LC3I, P62, p-ULK1ser757, and Beclin-1). CTRL, vehicle-treated (PBS) healthy control mice, n = 7–9. C26 + PBS = C26
tumor-bearing mice administered with a vehicle (PBS), n = 7. C26 + sACVR/b = C26 tumor-bearing mice administered with sACVR before the tumor formation and
replaced by a vehicle (PBS) after the tumor formation, n = 7. C26 + sACVR/c = C26 tumor-bearing mice continuously administered with sACVR throughout the
experiment, n = 8. The symbol ∗ depicts statistical significance p < 0.05 and the symbol ∗∗ depicts statistical significance p < 0.01. For the C26 effect,
tumor-bearing groups were pooled. Data is expressed as means ± SE. Representative blots were cropped from the original blot images (Supplementary Figures 9,
11, 12). Representative blots with same IDs and analyzed in the same run are aligned on top of each other and share the same representative control blot (GAPDH).
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DISCUSSION
We demonstrated that muscle hypertrophy induced by blocking
ACVR2B ligands increased markers of unfolded protein response
(UPR) and the reduced form of glutathione. On the other
hand, experimental C26 cancer cachexia was accompanied by
decreased levels of reduced glutathione, indicating a decline in
antioxidant defense capacity in skeletal muscle. Interestingly,
blocking ACVR2B ligands restored this decline. Moreover, we
showed that selective UPR was induced in the liver, but not
in skeletal muscle during the onset of rapid weight loss in
experimental cancer.
We (Nissinen et al., 2018) and others (Cai et al., 2004;
Zhou et al., 2010) have previously shown that the prevention
of cancer cachexia without any effect on tumor growth
improves survival in experimental mouse models. This result
suggests a possible causality between the prevention of muscle
loss and improved survival in cachexia, but its underlying
mechanisms are unknown. More specifically, we showed that a
soluble growth factor receptor, namely sACVR2B-Fc, improved
survival in C26 cancer cachexia only when the treatment
continued after the tumor formation, whereas a discontinued
prophylactic treatment had no positive survival effects (Nissinen
et al., 2018). In the present study, we further investigated
the tumor-bearing mice and elucidated the role of biological
processes regulating protein homeostasis. We observed altered
redox balance, which shifted toward increased oxidative stress
manifested by decreased levels of reduced glutathione (GSH)
resulting in an increased ratio of oxidized to reduced glutathione
(GSSG/GSH) in the skeletal muscle of tumor-bearing mice. The
result is consistent with previous studies in which hallmarks
of altered redox state were manifested by decreased levels
of GSH (Ham et al., 2014) and a depletion of antioxidant
peptides (glutathione, anserine, and carnosine), accompanied
by a shift of the ratio of mannitol and mannose toward
the oxidized form (Der-Torossian et al., 2013) in the skeletal
muscle of tumor-bearing mice. Interestingly, together with
improving survival (Nissinen et al., 2018), only the continued
blocking of ACVR2B ligands restored glutathione levels in
cachectic skeletal muscle in line with the levels in the
healthy mice. Moreover, blocking ACVR2B ligands increased
the reduced form of glutathione in healthy mice as well,
suggesting that the effect is not limited to cachectic muscle
only. This supports the earlier study in which the absence of
normal myostatin signaling per se increased GSH concentration
(Ploquin et al., 2012). We also observed that muscle GSH
concentration correlated positively with adipose tissue mass,
skeletal muscle mass and change in body mass (last 2 days
of the experiment) as well as negatively with tumor mass,
suggesting that skeletal muscle GSH depletion is associated with
the severity of the cachexia (Supplementary Figures 2A–D).
Indeed, in a previous study, administration of glycine, which
is a precursor for glutathione, improved muscle function and
inhibited muscle wasting in C26 cachexia (Ham et al., 2014),
suggesting that the reduced GSH may have an impact on the
cachexia progression and restoring the redox balance may be
beneficial.
The increase in GSH may also be a compensatory mechanism
for increased oxidative damage/stress after a single or repeated
sACVR administration. Unlike in healthy mice, protein carbonyls
were, however, unchanged in tumor-bearing mice with or
without blocking ACVR2B ligands. The accumulation of
oxidatively damaged proteins is also known to induce proteasome
activity intended to achieve their removal (Radak et al., 2000).
Therefore, no difference in oxidatively modified protein levels
may be explained by their increased removal. To support
this assumption we observed increased markers of protein
degradation (Nissinen et al., 2018) and in the current study
increased markers of autophagy. Thus, a possible increase of
oxidative protein modification cannot be discarded in tumor-
bearing mice. Heat shock proteins are known to be induced, for
example, by oxidative and metabolic stress (Niforou et al., 2014).
We did not observe induction of the expression HSPs 60, 70,
and 90 in healthy skeletal muscle, which does not support the
assumption that sACVR2B-Fc administration increases cellular
and especially oxidative stress. However, the expression of
HSP25, which is also known to protect cells from oxidative
stress (Escobedo et al., 2004) was also upregulated in healthy
and cachectic sACVR administered mice, the effect being
more profound in healthy muscle. This result is in line with
previous literature in which skeletal muscle hypertrophy was
observed (Huey, 2006; Frier and Locke, 2007; Huey et al.,
2010), suggesting that induction of HSP25 regulates muscle
homeostasis during rapid muscle hypertrophy. We analyzed
only HSP content to assess heat shock response and not their
subcellular localization, which is a key feature of their function
(Paulsen et al., 2007, 2009). Future studies are warranted to
investigate the effect of blocking ACVR2B ligands on oxidative
stress and redox regulation as well as HSP localization in more
detail.
To further investigate muscle protein homeostasis, we
analyzed several indicators of unfolded protein response (UPR),
a process that is also known to be induced by ER stress
and oxidative stress (Cao and Kaufman, 2014). We observed
that ER stress and UPR are not induced at the onset of
C26 induced cachexia and, if anything, UPR may instead be
downregulated. These observations are in line with decreased
p-eIF2α in C26 tumor-bearing mice (Penna et al., 2010).
However, they are contrary to a previous study in which UPR
in skeletal muscle was upregulated in two other commonly
used experimental animal models of cancer cachexia: LLC and
Apcmin/+ mice. Interestingly, UPR seems to protect muscles
from further wasting in these experimental cancer models
(Bohnert et al., 2016; Gallot et al., 2018). The decreased UPR
indicators were associated with the severity of cachexia because
the downregulated UPR indicators (p-eIF2α, HSP47 and p-JNK)
correlated positively with the change in body mass between
the last 2 days of the experiment and negatively with the
tumor mass (Supplementary Figures 3A–F). Alternatively, the
decreased levels of UPR indicators in skeletal muscle that we
observed in tumor-bearing mice could possibly be explained
by decreased overall protein synthesis (Nissinen et al., 2018),
which would reduce the demand of the folding of the nascent
newly synthesized proteins. To support this, p-eIF2α, HSP47,
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and p-JNK correlated positively with muscle protein synthesis
(Supplementary Figures 4A–C). Another possible mechanism
downregulating these indicators may be a decrease in physical
activity that we previously reported (Nissinen et al., 2018)
because HSP47 has been shown to decline during muscle
unloading (Oguro et al., 2003) and phosphorylation of JNK
has been shown to be inducible by resistance exercise (Hentila
et al., 2018) and mechanical strain (Martineau and Gardiner,
2001).
Interestingly, many of the downregulated UPR markers
in cancer were or tended to be increased in mice that
received continued sACVR2B-Fc treatment, compared with
other tumor-bearing mice. In healthy mice, 2-week sACVR2B-Fc
administration increased the same UPR markers (GRP78, HSP47,
and p-eIF2α) that also tended to be upregulated in sACVR2B-
Fc administered C26 tumor-bearing mice. This suggests that
these UPR indicators are upregulated more ubiquitously by
sACVR2B-Fc administration. However, UPR indicators were not
induced acutely 1 or 2 days after a single administration of
sACVR2B-Fc, even though the protein synthesis was greatly
induced, as we previously reported (Hulmi et al., 2013a). This
is contrary to another stimulus, increasing protein synthesis,
resistance exercise (RE), which has been shown to induce
UPR 1 and 2 days after the RE bout (Ogborn et al., 2014;
Hentila et al., 2018). Thus, it is suggested that UPR activation
following sACVR2B-Fc ligand blocking is delayed compared with
a RE bout. Previously, activation of UPR has been shown to
inhibit mTORC1 signaling (Deldicque et al., 2010, 2011) and
was suggested to act as a molecular break, suppressing protein
synthesis during rapid muscle growth (Hamilton et al., 2014).
Indeed, based on growth curves, the rate of muscle growth
seemed to reach a plateau after 10 days during the sACVR2B-Fc
administration (Hulmi et al., 2013a), which might be attributed
to the induction of UPR and consequently blunted muscle
growth.
We previously reported increased hepatic protein synthesis
and induction of acute phase response (APR), suggesting altered
protein homeostasis in the liver of tumor-bearing mice (Nissinen
et al., 2018). Thus, we also analyzed UPR indicators in the liver
of the tumor-bearing mice. In contrast to skeletal muscle, PERK,
p-eIF2α, and GRP78 were increased by C26, whereas ATF4
protein content was strongly decreased. These results suggest that
specific branches of UPR are activated in the liver of the tumor-
bearing mice while some indicators may respond with a strong
decrease. In a previous study, specific UPR markers have been
associated with the severity of the cachexia: the pro-apoptotic
indicators were especially associated with the progression of
cachexia (Narsale et al., 2015). To analyze the maladaptive UPR
branch that drives apoptosis, we analyzed the content of the
ER stress-specific apoptosis marker caspase 12 (Szegezdi et al.,
2006) from the livers of tumor-bearing mice. Interestingly, the
content of the cleaved, active caspase 12 was unchanged, but the
uncleaved pro caspase 12 was decreased in the liver of tumor-
bearing mice. In addition, another ER-stress-associated pro-
apoptotic indicator, JNK phosphorylation (Urano et al., 2000;
Szegezdi et al., 2006) and the apoptosis marker cleaved caspase
3 were unchanged. This suggests that ER-stress-driven apoptosis
was not induced in the liver of tumor-bearing mice. Nevertheless,
the hepatic UPR markers GRP78 and ATF4 correlated positively
with the change in body mass (the last 2 days of the experiment)
(Supplementary Figures 5A,B) and ATF4 correlated negatively
with the tumor mass (Supplementary Figure 5C), suggesting that
also some of the hepatic UPR indicators may be associated with
the severity of cachexia.
As a third biological process that is connected to redox balance
(Lee et al., 2012) and UPR (Yorimitsu et al., 2006) and which
contributes to the muscle protein homeostasis, we investigated
the indicators of the autophagy-lysosome pathway that is
responsible for the degradation and recycling of unnecessary
and/or damaged proteins and organelles (Sandri, 2013) from
the tumor-bearing mice. We observed increased content of
lipidated LC3, increased ratio of LC3II and LC3I (LC3II/LC3I),
Lc3b mRNA and Beclin-1 in the skeletal muscle of C26 tumor-
bearing mice, which indicates increased autophagosome content
and the induction of autophagy, respectively. These results were
accompanied by increased P62 protein and unchanged P62
mRNA levels, suggesting decreased clearance of autophagosomes
(Klionsky et al., 2016). Our results are consistent with the
previous studies conducted with experimental animal models
and also in cachectic humans (Penna et al., 2013; Aversa et al.,
2016; Molinari et al., 2017), clearly indicating that autophagy
is induced in cachectic muscle and that the clearance of the
autophagosomes may be inhibited. Even though the continued
sACVR2B-Fc treatment previously inhibited the muscle wasting
in the tumor-bearing mice (Nissinen et al., 2018) and has
decreased markers of autophagy in healthy mice (Hulmi et al.,
2013b), the novelty of our present study was that the sACVR2B-
Fc treatment did not inhibit the increase in autophagy that
was observed 11 days after the C26 inoculation. These results
suggest that autophagy contributes to the muscle wasting
together with the ubiquitin-proteasome system, which was also
upregulated in the muscle of the C26 tumor-bearing mice
despite the sACVR treatment (Nissinen et al., 2018). In the
liver, as in the skeletal muscle, lipidated LC3 content and
LC3II/LC3I were increased in C26 tumor-bearing mice but
not P62, suggesting increased autophagosome content without
impairment in the autophagic flux. Our results suggest that
cancer cachexia induces aberration in the hepatic proteostasis,
which is compensated by the induction of autophagy and UPR
without any evident ER-stress related apoptosis. The induction
of autophagy may also be explained by decreased feed intake,
a known stimulus for autophagy activation (Sandri, 2010,
2013).
In conclusion, experimental cancer cachexia decreased
the anti-oxidant defense capacity manifested by decreased
glutathione content in skeletal muscle. However, sACVR2B-
Fc administration increased glutathione in both healthy and
cachectic muscle, suggesting that it increases anti-oxidant defense
capacity in skeletal muscle. Based on the correlations of the
data, we suggest that alterations in the processes contributing to
protein homeostasis are associated with the severity of cachexia.
The induction of UPR in the liver but not in skeletal muscle
indicates that the protein homeostasis is altered in a tissue-
specific manner in C26 cancer cachexia.
Frontiers in Physiology | www.frontiersin.org 14 January 2019 | Volume 9 | Article 1917
fphys-09-01917 January 16, 2019 Time: 18:44 # 15
Hentilä et al. The Effects of Cachexia and Blocking Myostatin/Activins on Proteostasis
AUTHOR CONTRIBUTIONS
JJH, JH, and TN designed the cancer experiments. JJH and OR
designed the acute study. TN and JH carried out the cancer
experiments. JJH carried out the acute sACVR2B-Fc experiments
with the healthy mice. MS and SL assisted in the in vivo
experiments. JH drafted the manuscript with the help from JJH,
MA, and TN. JH carried out the analysis with the help from
TN, MA, and AK. AP and OR designed and produced the
recombinant sACVR2B-Fc used in the study. All authors read
and approved the final manuscript.
FUNDING
This work was supported by Academy of Finland (Decision Nos.
137787 and 275922 to JJH), the Finnish Cultural Foundation
personal grant (JH), Jenny and Antti Wihuri Foundation (TN),
and COST Action (CA16112 to MA).
ACKNOWLEDGMENTS
We would like to thank Juulia Lautaoja, Hongqiang Ma,
Bernardo Oliveira, Tanja Holopainen, Sira Karvinen, Kaisa-Leena
Tulla, Mervi Matero, Risto Puurtinen, Aila Ollikainen, Eliisa
Kiukkanen, and Taina Vihavainen for their help.
SUPPLEMENTARY MATERIAL




Amthor, H., Macharia, R., Navarrete, R., Schuelke, M., Brown, S. C., Otto, A., et al.
(2007). Lack of myostatin results in excessive muscle growth but impaired force
generation. Proc. Natl. Acad. Sci. U.S.A. 104, 1835–1840. doi: 10.1073/pnas.
0604893104
Argiles, J. M., Busquets, S., Stemmler, B., and Lopez-Soriano, F. J. (2014). Cancer
cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754–762.
doi: 10.1038/nrc3829
Atalay, M., Oksala, N. K. J., Laaksonen, D. E., Khanna, S., Nakao, C.,
Lappalainen, J., et al. (2004). Exercise training modulates heat shock protein
response in diabetic rats. J. Appl. Physiol. 97, 605–611. doi: 10.1152/japplphysiol.
01183.2003
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall,
A. E., et al. (2013). A single ascending-dose study of muscle regulator ace-031
in healthy volunteers. Muscle Nerve 47, 416–423. doi: 10.1002/mus.23539
Aversa, Z., Pin, F., Lucia, S., Penna, F., Verzaro, R., Fazi, M., et al. (2016).
Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci.
Rep. 6:30340. doi: 10.1038/srep30340
Bohnert, K. R., Gallot, Y. S., Sato, S., Xiong, G., Hindi, S. M., and Kumar, A.
(2016). Inhibition of ER stress and unfolding protein response pathways causes
skeletal muscle wasting during cancer cachexia. FASEB J. 30, 3053–3068.
doi: 10.1096/fj.201600250RR
Cai, D., Frantz, J. D., Tawa, N. E. J., Melendez, P. A., Oh, B.-C., Lidov, H. G. W.,
et al. (2004). IKKbeta/NF-kappaB activation causes severe muscle wasting in
mice. Cell 119, 285–298. doi: 10.1016/j.cell.2004.09.027
Cao, S. S., and Kaufman, R. J. (2014). Endoplasmic reticulum stress and oxidative
stress in cell fate decision and human disease. Antioxid. Redox Signal. 21,
396–413. doi: 10.1089/ars.2014.5851
Choi, Y., Oh, D.-Y., Kim, T.-Y., Lee, K.-H., Han, S.-W., Im, S.-A., et al. (2015).
Skeletal muscle depletion predicts the prognosis of patients with advanced
pancreatic cancer undergoing palliative chemotherapy, independent of body
mass index. PLoS One 10:e0139749. doi: 10.1371/journal.pone.0139749
Cray, C., Zaias, J., and Altman, N. H. (2009). Acute phase response in animals: a
review. Comp. Med. 59, 517–526.
Deldicque, L., Bertrand, L., Patton, A., Francaux, M., and Baar, K. (2011). ER stress
induces anabolic resistance in muscle cells through PKB-induced blockade of
mTORC1. PLoS One 6:e20993. doi: 10.1371/journal.pone.0020993
Deldicque, L., Cani, P. D., Philp, A., Raymackers, J.-M., Meakin, P. J., Ashford,
M. L. J., et al. (2010). The unfolded protein response is activated in skeletal
muscle by high-fat feeding: potential role in the downregulation of protein
synthesis. Am. J. Physiol. Endocrinol. Metab. 299, E695–E705. doi: 10.1152/
ajpendo.00038.2010
Der-Torossian, H., Wysong, A., Shadfar, S., Willis, M. S., McDunn, J., and Couch,
M. E. (2013). Metabolic derangements in the gastrocnemius and the effect
of Compound A therapy in a murine model of cancer cachexia. J. Cachexia
Sarcopenia Muscle 4, 145–155. doi: 10.1007/s13539-012-0101-7
Escobedo, J., Pucci, A. M., and Koh, T. J. (2004). HSP25 protects skeletal muscle
cells against oxidative stress. Free Radic. Biol. Med. 37, 1455–1462. doi: 10.1016/
j.freeradbiomed.2004.07.024
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L.,
et al. (2011). Definition and classification of cancer cachexia: an international
consensus. Lancet Oncol. 12, 489–495. doi: 10.1016/S1470-2045(10)70218-7
Frier, B. C., and Locke, M. (2007). Heat stress inhibits skeletal muscle hypertrophy.
Cell Stress Chaperones 12, 132–141. doi: 10.1379/CSC-233R.1
Gallot, Y. S., Bohnert, K. R., Straughn, A. R., Xiong, G., Hindi, S. M., and Kumar, A.
(2018). PERK regulates skeletal muscle mass and contractile function in adult
mice. FASEB J. doi: 10.1096/fj.201800683RR [Epub ahead of print].
Ham, D. J., Murphy, K. T., Chee, A., Lynch, G. S., and Koopman, R. (2014). Glycine
administration attenuates skeletal muscle wasting in a mouse model of cancer
cachexia. Clin. Nutr. 33, 448–458. doi: 10.1016/j.clnu.2013.06.013
Hamilton, D. L., Philp, A., MacKenzie, M. G., Patton, A., Towler, M. C., Gallagher,
I. J., et al. (2014). Molecular brakes regulating mTORC1 activation in skeletal
muscle following synergist ablation. Am. J. Physiol. Endocrinol. Metab. 307,
E365–E373. doi: 10.1152/ajpendo.00674.2013
Hentila, J., Ahtiainen, J. P., Paulsen, G., Raastad, T., Hakkinen, K., Mero, A. A., et al.
(2018). Autophagy is induced by resistance exercise in young men but unfolded
protein response is induced regardless of age. Acta Physiol. 224:e13069.
doi: 10.1111/apha.13069
Hetz, C., Chevet, E., and Oakes, S. A. (2015). Proteostasis control by the unfolded
protein response. Nat. Cell Biol. 17, 829–838. doi: 10.1038/ncb3184
Hoogaars, W. M. H., Mouisel, E., Pasternack, A., Hulmi, J. J., Relizani, K.,
Schuelke, M., et al. (2012). Combined effect of AAV-U7-induced dystrophin
exon skipping and soluble activin Type IIB receptor in mdx mice. Hum. Gene
Ther. 23, 1269–1279. doi: 10.1089/hum.2012.056
Huey, K. A. (2006). Regulation of HSP25 expression and phosphorylation in
functionally overloaded rat plantaris and soleus muscles. J. Appl. Physiol. 100,
451–456. doi: 10.1152/japplphysiol.01022.2005
Huey, K. A., Burdette, S., Zhong, H., and Roy, R. R. (2010). Early response of heat
shock proteins to functional overload of the soleus and plantaris in rats and
mice. Exp. Physiol. 95, 1145–1155. doi: 10.1113/expphysiol.2010.054692
Hulmi, J. J., Hentilä, J., DeRuisseau, K. C., Oliveira, B. M., Papaioannou, K. G.,
Autio, R., et al. (2016). Effects of muscular dystrophy, exercise and blocking
activin receptor IIB ligands on the unfolded protein response and oxidative
stress. Free Radic. Biol. Med. 99, 308–322. doi: 10.1016/j.freeradbiomed.2016.
08.017
Hulmi, J. J., Oliveira, B. M., Silvennoinen, M., Hoogaars, W. M. H., Ma, H.,
Pierre, P., et al. (2013a). Muscle protein synthesis, mTORC1/MAPK/Hippo
signaling, and capillary density are altered by blocking of myostatin and
activins. Am. J. Physiol. Endocrinol. Metab. 304, E41–E50. doi: 10.1152/ajpendo.
00389.2012
Hulmi, J. J., Oliveira, B. M., Silvennoinen, M., Hoogaars, W. M. H., Pasternack, A.,
Kainulainen, H., et al. (2013b). Exercise restores decreased physical activity
levels and increases markers of autophagy and oxidative capacity in
Frontiers in Physiology | www.frontiersin.org 15 January 2019 | Volume 9 | Article 1917
fphys-09-01917 January 16, 2019 Time: 18:44 # 16
Hentilä et al. The Effects of Cachexia and Blocking Myostatin/Activins on Proteostasis
myostatin/activin-blocked mdx mice. Am. J. Physiol. Endocrinol. Metab. 305,
E171–E182. doi: 10.1152/ajpendo.00065.2013
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo
Arozena, A., et al. (2016). Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy 12, 1–222. doi: 10.1080/
15548627.2015.1100356
Lappalainen, Z., Lappalainen, J., Oksala, N. K. J., Laaksonen, D. E., Khanna, S., Sen,
C. K., et al. (2009). Diabetes impairs exercise training-associated thioredoxin
response and glutathione status in rat brain. J. Appl. Physiol. 106, 461–467.
doi: 10.1152/japplphysiol.91252.2008
Lee, J., Giordano, S., and Zhang, J. (2012). Autophagy, mitochondria and oxidative
stress: cross-talk and redox signalling. Biochem. J. 441, 523–540. doi: 10.1042/
BJ20111451
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson,
K. N., et al. (2005). Regulation of muscle growth by multiple ligands signaling
through activin type II receptors. Proc. Natl. Acad. Sci. U.S.A. 102, 18117–18122.
doi: 10.1073/pnas.0505996102
Marabita, M., Baraldo, M., Solagna, F., Ceelen, J. J. M., Sartori, R., Nolte, H.,
et al. (2016). S6K1 is required for increasing skeletal muscle force during
hypertrophy. Cell Rep. 17, 501–513. doi: 10.1016/j.celrep.2016.09.020
Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar,
L. J., et al. (2013). Cancer cachexia in the age of obesity: skeletal muscle
depletion is a powerful prognostic factor, independent of body mass index.
J. Clin. Oncol. 31, 1539–1547. doi: 10.1200/JCO.2012.45.2722
Martineau, L. C., and Gardiner, P. F. (2001). Insight into skeletal muscle
mechanotransduction: MAPK activation is quantitatively related to tension.
J. Appl. Physiol. 91, 693–702. doi: 10.1152/jappl.2001.91.2.693
Molinari, F., Pin, F., Gorini, S., Chiandotto, S., Pontecorvo, L., Penna, F., et al.
(2017). The mitochondrial metabolic reprogramming agent trimetazidine as
an “exercise mimetic” in cachectic C26-bearing mice. J. Cachexia Sarcopenia
Muscle 8, 954–973. doi: 10.1002/jcsm.12226
Narsale, A. A., Enos, R. T., Puppa, M. J., Chatterjee, S., Murphy, E. A., Fayad, R.,
et al. (2015). Liver inflammation and metabolic signaling in ApcMin/+ mice:
the role of cachexia progression. PLoS One 10:e0119888. doi: 10.1371/journal.
pone.0119888
Niforou, K., Cheimonidou, C., and Trougakos, I. P. (2014). Molecular chaperones
and proteostasis regulation during redox imbalance. Redox Biol. 2, 323–332.
doi: 10.1016/j.redox.2014.01.017
Nissinen, T. A., Degerman, J., Räsänen, M., Poikonen, A. R., Koskinen, S.,
Mervaala, E., et al. (2016). Systemic blockade of ACVR2B ligands prevents
chemotherapy-induced muscle wasting by restoring muscle protein synthesis
without affecting oxidative capacity or atrogenes. Sci. Rep. 6:32695. doi: 10.
1038/srep32695
Nissinen, T. A., Hentila, J., Penna, F., Lampinen, A., Lautaoja, J. H., Fachada, V.,
et al. (2018). Treating cachexia using soluble ACVR2B improves survival, alters
mTOR localization, and attenuates liver and spleen responses. J. Cachexia
Sarcopenia Muscle 9, 514–529. doi: 10.1002/jcsm.12310
Ogborn, D. I., McKay, B. R., Crane, J. D., Parise, G., and Tarnopolsky, M. A. (2014).
The unfolded protein response is triggered following a single, unaccustomed
resistance-exercise bout. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307,
R664–R669. doi: 10.1152/ajpregu.00511.2013
Oguro, A., Sakurai, T., Otawa, M., Okuno, M., and Atomi, Y. (2003). The
content of heat shock protein 47 (HSP47), a collagen-specific stress protein,
changes with gravitational conditions in skeletal muscle. Biol. Sci. Space 17,
206–207.
Paulsen, G., Lauritzen, F., Bayer, M. L., Kalhovde, J. M., Ugelstad, I., Owe, S. G.,
et al. (2009). Subcellular movement and expression of HSP27, alphaB-crystallin,
and HSP70 after two bouts of eccentric exercise in humans. J. Appl. Physiol. 107,
570–582. doi: 10.1152/japplphysiol.00209.2009
Paulsen, G., Vissing, K., Kalhovde, J. M., Ugelstad, I., Bayer, M. L., Kadi, F., et al.
(2007). Maximal eccentric exercise induces a rapid accumulation of small heat
shock proteins on myofibrils and a delayed HSP70 response in humans. Am.
J. Physiol. Regul. Integr. Comp. Physiol. 293, R844–R853. doi: 10.1152/ajpregu.
00677.2006
Penna, F., Bonetto, A., Muscaritoli, M., Costamagna, D., Minero, V. G., Bonelli, G.,
et al. (2010). Muscle atrophy in experimental cancer cachexia: is the IGF-1
signaling pathway involved? Int. J. Cancer 127, 1706–1717. doi: 10.1002/ijc.
25146
Penna, F., Costamagna, D., Pin, F., Camperi, A., Fanzani, A., Chiarpotto, E. M.,
et al. (2013). Autophagic degradation contributes to muscle wasting in cancer
cachexia. Am. J. Pathol. 182, 1367–1378. doi: 10.1016/j.ajpath.2012.12.023
Pistilli, E. E., Bogdanovich, S., Goncalves, M. D., Ahima, R. S., Lachey, J., Seehra, J.,
et al. (2011). Targeting the activin type IIB receptor to improve muscle mass
and function in the mdx mouse model of Duchenne muscular dystrophy. Am.
J. Pathol. 178, 1287–1297. doi: 10.1016/j.ajpath.2010.11.071
Ploquin, C., Chabi, B., Fouret, G., Vernus, B., Feillet-Coudray, C., Coudray, C.,
et al. (2012). Lack of myostatin alters intermyofibrillar mitochondria
activity, unbalances redox status, and impairs tolerance to chronic repetitive
contractions in muscle. Am. J. Physiol. Endocrinol. Metab. 302, E1000–E1008.
doi: 10.1152/ajpendo.00652.2011
Radak, Z., Sasvari, M., Nyakas, C., Pucsok, J., Nakamoto, H., and Goto, S. (2000).
Exercise preconditioning against hydrogen peroxide-induced oxidative damage
in proteins of rat myocardium. Arch. Biochem. Biophys. 376, 248–251. doi:
10.1006/abbi.2000.1719
Relizani, K., Mouisel, E., Giannesini, B., Hourde, C., Patel, K., Morales Gonzalez, S.,
et al. (2014). Blockade of ActRIIB signaling triggers muscle fatigability and
metabolic myopathy. Mol. Ther. 22, 1423–1433. doi: 10.1038/mt.2014.90
Renjini, R., Gayathri, N., Nalini, A., and Srinivas Bharath, M. M. (2012). Oxidative
damage in muscular dystrophy correlates with the severity of the pathology: role
of glutathione metabolism. Neurochem. Res. 37, 885–898. doi: 10.1007/s11064-
011-0683-z
Sandri, M. (2010). Autophagy in skeletal muscle. FEBS Lett. 584, 1411–1416.
doi: 10.1016/j.febslet.2010.01.056
Sandri, M. (2013). Protein breakdown in muscle wasting: role of autophagy-
lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45, 2121–2129.
doi: 10.1016/j.biocel.2013.04.023
Sandri, M. (2016). Protein breakdown in cancer cachexia. Semin. Cell Dev. Biol. 54,
11–19. doi: 10.1016/j.semcdb.2015.11.002
Schneider, K., and Bertolotti, A. (2015). Surviving protein quality control
catastrophes - from cells to organisms. J. Cell Sci. 128, 3861–3869. doi: 10.1242/
jcs.173047
Screen, M., Raheem, O., Holmlund-Hampf, J., Jonson, P. H., Huovinen, S.,
Hackman, P., et al. (2014). Gene expression profiling in tibial muscular
dystrophy reveals unfolded protein response and altered autophagy. PLoS One
9:e90819. doi: 10.1371/journal.pone.0090819
Szegezdi, E., Logue, S. E., Gorman, A. M., and Samali, A. (2006). Mediators
of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7, 880–885.
doi: 10.1038/sj.embor.7400779
Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., et al.
(2000). Coupling of stress in the ER to activation of JNK protein kinases
by transmembrane protein kinase IRE1. Science 287, 664–666. doi: 10.1126/
science.287.5453.664
von Haehling, S., and Anker, S. D. (2014). Prevalence, incidence and clinical impact
of cachexia: facts and numbers-update 2014. J. Cachexia Sarcopenia Muscle 5,
261–263. doi: 10.1007/s13539-014-0164-8
Whitham, M., Parker, B. L., Friedrichsen, M., Hingst, J. R., Hjorth, M., Hughes,
W. E., et al. (2018). Extracellular vesicles provide a means for tissue crosstalk
during exercise. Cell Metab. 27, 237.e4–251.e4. doi: 10.1016/j.cmet.2017.12.001
Yorimitsu, T., Nair, U., Yang, Z., and Klionsky, D. J. (2006). Endoplasmic reticulum
stress triggers autophagy. J. Biol. Chem. 281, 30299–30304. doi: 10.1074/jbc.
M607007200
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., et al. (2010). Reversal of
cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged
survival. Cell 142, 531–543. doi: 10.1016/j.cell.2010.07.011
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Hentilä, Nissinen, Korkmaz, Lensu, Silvennoinen, Pasternack,
Ritvos, Atalay and Hulmi. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 16 January 2019 | Volume 9 | Article 1917
